Winslow Capital Management LLC purchased a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 1,267,618 shares of the company’s stock, valued at approximately $260,191,000.
A number of other institutional investors also recently modified their holdings of RVMD. Burkett Financial Services LLC bought a new stake in shares of Revolution Medicines during the 3rd quarter worth $27,000. Contravisory Investment Management Inc. acquired a new stake in Revolution Medicines in the second quarter valued at about $32,000. Johnson Financial Group Inc. bought a new position in Revolution Medicines in the second quarter valued at about $37,000. Silvant Capital Management LLC bought a new position in Revolution Medicines in the second quarter valued at about $41,000. Finally, Northwestern Mutual Wealth Management Co. bought a new position in Revolution Medicines in the second quarter valued at about $41,000. Institutional investors and hedge funds own 94.34% of the company’s stock.
Revolution Medicines Trading Up 0.8%
Shares of RVMD stock opened at $160.63 on Friday. Revolution Medicines, Inc. has a twelve month low of $69.50 and a twelve month high of $224.31. The stock’s fifty day simple moving average is $190.01 and its 200 day simple moving average is $161.04. The company has a quick ratio of 8.34, a current ratio of 8.36 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $34.74 billion, a P/E ratio of -17.63 and a beta of 1.44.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported ($1.90) EPS for the quarter, beating the consensus estimate of ($2.35) by $0.45. The firm had revenue of $197.56 million during the quarter, compared to the consensus estimate of $25.58 million. During the same quarter in the prior year, the business posted ($1.61) earnings per share. As a group, sell-side analysts predict that Revolution Medicines, Inc. will post -7.41 EPS for the current fiscal year.
Insider Buying and Selling
In other news, Director Elizabeth Anderson sold 10,143 shares of the company’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $193.04, for a total value of $1,958,004.72. Following the completion of the transaction, the director owned 4,333 shares of the company’s stock, valued at $836,442.32. This represents a 70.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Jack Anders sold 35,750 shares of the firm’s stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $188.10, for a total transaction of $6,724,575.00. Following the completion of the transaction, the chief financial officer owned 119,216 shares of the company’s stock, valued at approximately $22,424,529.60. This trade represents a 23.07% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 273,901 shares of company stock valued at $53,970,418 over the last three months. Insiders own 7.60% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the stock. Morgan Stanley dropped their target price on shares of Revolution Medicines from $272.00 to $247.00 and set an “overweight” rating for the company in a report on Friday, November 13th. Stifel Nicolaus lifted their price target on shares of Revolution Medicines from $215.00 to $230.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. Bank of America decreased their price target on shares of Revolution Medicines from $265.00 to $264.00 and set a “buy” rating on the stock in a report on Friday, October 9th. HC Wainwright reiterated a “buy” rating and set a $350.00 price objective on shares of Revolution Medicines in a research report on Tuesday, November 17th. Finally, Truist Financial reissued a “buy” rating and issued a $261.00 price objective (up from $241.00) on shares of Revolution Medicines in a research note on Thursday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $262.75.
View Our Latest Research Report on Revolution Medicines
Top Revolution Medicines Stories
These are some of the RVMD stories that stood out recently:
- Positive Sentiment: The company reported encouraging updated Phase 1/2 results for RASONQUE plus chemotherapy as a potential first-line treatment for metastatic pancreatic cancer. Further clinical progress could support the drug’s longer-term opportunity, though the release excerpt does not provide detailed efficacy or safety figures. Article: Updated Phase 1/2 Data for RASONQUE Plus Chemotherapy
- Neutral Sentiment: A separate report frames the company’s performance against competitor Erasca, suggesting competitive developments are part of the sector narrative; the provided headline does not give enough detail to assess the implications for RVMD. Article: Erasca Throws Down a Gauntlet—and Revolution Throws It Right Back
- Negative Sentiment: Insider Stephen Kelsey sold 27,160 shares for about $4.56 million, an 8.66% reduction in his holdings. He retained 286,307 shares, but the sale may add to cautious sentiment. Article: Revolution Medicines Insider Sells 27,160 Shares
Revolution Medicines Profile
Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.
See Also
- Five stocks we like better than Revolution Medicines
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report).
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
